文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠道微生物组和血浆胆汁酸分析可对患者进行分层，以进行抗糖尿病治疗。

Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.

机构信息

Shanghai National Research Centre for Endocrine and Metabolic Diseases, State Key Laboratory of Medical Genomics, Shanghai Institute for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 200025, Shanghai, China.

BGI-Shenzhen, China National GeneBank-Shenzhen, 518083, Shenzhen, China.

出版信息

Nat Commun. 2017 Nov 27;8(1):1785. doi: 10.1038/s41467-017-01682-2.

DOI:10.1038/s41467-017-01682-2
PMID:29176714
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5702614/
Abstract

Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes (T2D) patients, which may beneficially affect metabolism. Acarbose increases the relative abundances of Lactobacillus and Bifidobacterium in the gut microbiota and depletes Bacteroides, thereby changing the relative abundance of microbial genes involved in BA metabolism. Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment. Our work highlights the potential for stratification of T2D patients based on their gut microbiota prior to treatment.

摘要

抗糖尿病药物可能调节肠道微生物群，从而改变血浆和粪便胆汁酸（BA）组成，这可能改善代谢健康。在这里，我们表明，阿卡波糖治疗而非格列吡嗪治疗可增加未经治疗的 2 型糖尿病（T2D）患者初级 BA 与次级 BA 的比例以及血浆中未结合 BA 的水平，这可能有益于代谢。阿卡波糖增加了肠道微生物群中乳杆菌和双歧杆菌的相对丰度，并消耗了拟杆菌，从而改变了参与 BA 代谢的微生物基因的相对丰度。阿卡波糖的治疗效果取决于治疗前的肠道微生物群组成。与肠道微生物群以普雷沃氏菌为主的患者相比，丰度较高的拟杆菌患者在阿卡波糖治疗后血浆 BA 变化更大，代谢参数改善更明显。我们的工作强调了在治疗前基于患者的肠道微生物群对 T2D 患者进行分层的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/9cc7d38a82bb/41467_2017_1682_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/fdb48ecfd443/41467_2017_1682_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/e22e930faa91/41467_2017_1682_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/90a9fb67b4c1/41467_2017_1682_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/b55c26eba05f/41467_2017_1682_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/9cc7d38a82bb/41467_2017_1682_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/fdb48ecfd443/41467_2017_1682_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/e22e930faa91/41467_2017_1682_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/90a9fb67b4c1/41467_2017_1682_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/b55c26eba05f/41467_2017_1682_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56cc/5702614/9cc7d38a82bb/41467_2017_1682_Fig5_HTML.jpg

相似文献

[1]
Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.

Nat Commun. 2017-11-27

[2]
Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus.

J Diabetes. 2015-9

[3]
Habitual Dietary Intake Affects the Altered Pattern of Gut Microbiome by Acarbose in Patients with Type 2 Diabetes.

Nutrients. 2021-6-19

[4]
Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats.

BMJ Open Diabetes Res Care. 2019-9-20

[5]
Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.

Front Endocrinol (Lausanne). 2020

[6]
Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial.

Diabetologia. 2022-10

[7]
Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.

Clin Rev Allergy Immunol. 2020-2

[8]
The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome.

mSphere. 2019-2-6

[9]
Unconjugated and secondary bile acid profiles in response to higher-fat, lower-carbohydrate diet and associated with related gut microbiota: A 6-month randomized controlled-feeding trial.

Clin Nutr. 2020-2

[10]
Fasting and refeeding triggers specific changes in bile acid profiles and gut microbiota.

J Diabetes. 2023-2

引用本文的文献

[1]
Probiotic Supplementation Improves Gut Microbiota in Chronic Metabolic and Cardio-Cerebrovascular Diseases Among Chinese Adults over 60: Study Using Cross-Sectional and Longitudinal Cohorts.

Microorganisms. 2025-6-27

[2]
Animal studies on the modulation of differential efficacy of polyethylene glycol loxenatide by intestinal flora.

Front Endocrinol (Lausanne). 2025-6-19

[3]
Metagenomic analysis revealing links between age, gut microbiota and bone loss in Chinese adults.

NPJ Metab Health Dis. 2025-5-3

[4]
Management Guidelines for Diabetic Patients With Hypertension.

J Diabetes. 2025-6

[5]
The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development.

Nat Rev Drug Discov. 2025-6-2

[6]
Grape polyphenols reduce fasting glucose and increase hyocholic acid in healthy humans: a meta-omics study.

NPJ Sci Food. 2025-5-27

[7]
Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial.

Front Endocrinol (Lausanne). 2025-5-6

[8]
Enhancement of Acarbose Production in sp. QQ-12 via Multiple Engineering Strategies.

J Agric Food Chem. 2025-5-28

[9]
Association Between Circulating Gremlin 2 and β-Cell Function Among Participants With Prediabetes and Type 2 Diabetes.

J Diabetes. 2025-4

[10]
Metabolic diseases in the East Asian populations.

Nat Rev Gastroenterol Hepatol. 2025-4-8

本文引用的文献

[1]
Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention.

Nat Med. 2017-6-19

[2]
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.

Nat Med. 2017-5-22

[3]
The Human Intestinal Microbiome in Health and Disease.

N Engl J Med. 2016-12-15

[4]
Personalized microbiome-based approaches to metabolic syndrome management and prevention.

J Diabetes. 2017-3

[5]
Standards of care for type 2 diabetes in China.

Diabetes Metab Res Rev. 2016-7

[6]
Human gut microbes impact host serum metabolome and insulin sensitivity.

Nature. 2016-7-13

[7]
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.

Cell Metab. 2016-6-16

[8]
Bile Acid Modifications at the Microbe-Host Interface: Potential for Nutraceutical and Pharmaceutical Interventions in Host Health.

Annu Rev Food Sci Technol. 2016-1-11

[9]
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota.

Nature. 2015-12-10

[10]
BlastKOALA and GhostKOALA: KEGG Tools for Functional Characterization of Genome and Metagenome Sequences.

J Mol Biol. 2015-11-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索